How Cosyntropin Works
Cosyntropin is a synthetic version of ACTH (adrenocorticotropic hormone), a 39-amino-acid peptide naturally produced by your pituitary gland. Your body releases ACTH in response to stress, circadian rhythms, and other physiological demands to signal your adrenal glands to produce cortisol—your body's main stress hormone.
Cosyntropin replicates ACTH's structure and function, binding to ACTH receptors on adrenal cells and triggering cortisol secretion within minutes. Doctors use this predictable response as a diagnostic window. By measuring your baseline cortisol and then your cortisol level after cosyntropin injection, they can determine whether your adrenal glands respond normally or show signs of dysfunction.
Clinical Uses: The Adrenal Insufficiency Test
The primary use of cosyntropin is diagnosing primary adrenal insufficiency (Addison's disease) and secondary adrenal insufficiency (caused by pituitary or hypothalamic dysfunction). Research indicates that cosyntropin stimulation testing is the gold-standard diagnostic tool for confirming adrenal insufficiency when baseline cortisol levels are ambiguous.
In the standard cosyntropin stimulation test, a patient receives a dose of cosyntropin intravenously or intramuscularly. A normal response shows cortisol rising to at least 18–20 μg/dL within 30–60 minutes. If cortisol doesn't rise adequately, it suggests the adrenal glands cannot respond—a hallmark of adrenal insufficiency.
Primary vs. Secondary Adrenal Insufficiency
Cosyntropin helps differentiate between two forms of adrenal insufficiency:
Primary adrenal insufficiency occurs when the adrenal glands themselves are damaged (e.g., autoimmune destruction, infection, or genetic conditions). In this case, the adrenal glands won't respond to cosyntropin stimulation, and cortisol remains low.
Secondary adrenal insufficiency results from inadequate ACTH production by the pituitary gland. The cosyntropin test can reveal whether the adrenals retain the capacity to produce cortisol if stimulated directly, which helps guide treatment decisions.
This distinction is clinically important because treatment approaches differ: primary insufficiency requires both cortisol and mineralocorticoid replacement, while secondary insufficiency typically requires only cortisol replacement.
The Testing Protocol
Cosyntropin stimulation tests come in two formats: the high-dose (250 μg) and low-dose (1 μg) protocols. The low-dose protocol has gained favour in recent years because it better mimics physiological ACTH levels and improves diagnostic accuracy for secondary insufficiency.
The procedure is straightforward:
- A baseline blood sample is drawn to measure cortisol (and sometimes ACTH and aldosterone).
- Cosyntropin is administered via IV or IM injection.
- Blood samples are collected at 30 and/or 60 minutes post-injection.
- Cortisol levels are measured and compared to baseline.
A normal cortisol response essentially rules out adrenal insufficiency, making cosyntropin testing highly valuable in clinical settings where symptoms are ambiguous.
Why Cosyntropin Matters
Adrenal insufficiency is a rare but serious condition. Undiagnosed, it can lead to life-threatening adrenal crisis—sudden hypotension, shock, and multi-organ failure. Early diagnosis via cosyntropin testing prevents these emergencies. Doctors use cosyntropin testing in patients with:
- Unexplained fatigue, hypotension, or electrolyte abnormalities
- Suspected pituitary dysfunction or tumours
- Long-term corticosteroid therapy (to assess adrenal recovery after stopping steroids)
- Septic shock (to identify occult adrenal insufficiency)
Regulatory Status and Clinical Evidence
Cosyntropin is FDA-approved in the United States and widely used in diagnostic endocrinology. The FDA approval reflects decades of clinical use and robust safety data. More than 38 clinical trials have evaluated cosyntropin stimulation testing across diverse patient populations, establishing its diagnostic reliability.
Unlike other peptides under investigation for metabolic conditions, cosyntropin's role is purely diagnostic—it identifies existing diseases rather than treating them. This diagnostic-only application means it carries minimal systemic side effects in the short-term testing context.
Comparing Cosyntropin to Other Diagnostic Approaches
Before cosyntropin became standard, clinicians relied on insulin tolerance tests (which induce hypoglycemia to stimulate ACTH and cortisol) or metyrapone tests (which block cortisol synthesis). Cosyntropin testing offers advantages: it's non-invasive, carries no risk of severe hypoglycemia, and produces rapid, reproducible results.
Some modern alternatives include baseline morning cortisol levels or late-night salivary cortisol testing for Cushing's syndrome screening, but cosyntropin stimulation remains the reference standard for diagnosing insufficiency. Like ACE-031 in muscle wasting research, cosyntropin occupies a specific, well-defined clinical niche where it excels.
Safety and Side Effects
Cosyntropin is generally very well tolerated. Most patients experience no adverse effects from the injection itself. Rarely, patients report mild flushing, itching, or transient hypertension during the test. True allergic reactions are extremely uncommon. Because the test lasts only 60 minutes and uses physiological doses of a natural hormone mimic, systemic toxicity is not a clinical concern.
Looking Forward
While cosyntropin's diagnostic role is established and unlikely to change, research continues into optimizing testing protocols and extending applications. Novel biomarkers and imaging modalities are being explored alongside traditional cosyntropin testing to improve early detection of adrenal disorders.
The Bottom Line
Cosyntropin is a precise diagnostic tool—not a treatment. It answers a specific clinical question: Are your adrenal glands capable of responding to hormonal signals? If the answer is no, further investigation and lifelong hormone replacement therapy may be needed. For patients with fatigue, weakness, or unexplained electrolyte imbalances, a cosyntropin test can be the difference between diagnosis and continued mystery.